A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...

MB-109 is Mustang’s regimen that combines MB-101, a chimeric antigen receptor (CAR)-T-cell therapy targeting interleukin 13 receptor alpha 2, with MB-108, which is licenced from Nationwide Children’s ...